83311-25-5

Usage

Uses

Used in Pharmaceutical Industry:
4-(Bromomethyl)-2-chlorobenzonitrile is used as a key intermediate in the synthesis of various pharmaceuticals. Its unique chemical structure allows for the creation of new drug molecules with potential therapeutic applications. 4-(broMoMethyl)-2-chlorobenzonitrile plays a crucial role in the development of medications that target a wide range of health conditions.
Used in Agrochemical Industry:
In the agrochemical sector, 4-(Bromomethyl)-2-chlorobenzonitrile is utilized as an intermediate for the production of pesticides and other agricultural chemicals. Its chemical properties make it suitable for the synthesis of compounds that can effectively control pests and diseases in crops, thereby contributing to increased agricultural productivity and food security.
Due to its versatility and reactivity, 4-(Bromomethyl)-2-chlorobenzonitrile holds potential for further applications in various industries, including the development of new materials and chemical processes. However, its use must be carefully managed to minimize its irritant effects on human health and the environment.

Upstream product

• 21423-84-7 2-chloro-4-methylbenzonitrile 
• 371764-78-2 2-chloro-4-(hydroxymethyl)benzonitrile 

Downstream Products

• 1236189-48-2 tert-butyl 1-(3-chloro-4-cyanobenzyl)azetidine-3-carboxylate 
• 1021873-79-9 5-chloro-1-(3-chloro-4-cyanobenzyl)-2-imino-1,2-dihydropyridine-3-carboxamide monohydrobromide 
• 1034188-44-7 ethyl 1-[(3-chloro-4-cyanophenyl)methyl]-1H-pyrazole-3-carboxylate 

Relevant academic research and scientific papers

COMPOUNDS AND USES THEREOF

The present invention features compounds useful in the treatment of neurological disorders and primary brain cancer. The compounds of the invention, alone or in combination with other pharmaceutically active agents, can be used for treating or preventing neurological disorders and primary brain cancer.

COMPOUNDS AND USES THEREOF

The present invention features compounds useful in the treatment of neurological disorders. The compounds of the invention, alone or in combination with other pharmaceutically active agents, can be used for treating or preventing neurological disorders.

THIAZALOPYRROLIDINE INHIBITORS OF ROR-GAMMA

Provided are novel compounds of Formula (I): pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are useful in the treatment of diseases and disorders mediated by ROR?. Also provided are pharmaceutical compositions comprising the novel compounds of Formula (I) and methods for their use in treating one or more inflammatory, metabolic, autoimmune and other diseases or disorders.

SUBSTITUTED OXADIAZOLE DERIVATIVES AS S1P AGONISTS IN THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISEASES

Disclosed are compounds of Formula (I) [INSERT CHEMICAL STRUCTURE HERE] (I) or pharmaceutically acceptable salts thereof, wherein Q is [INSERT CHEMICAL STRUCTURE HERE] or [INSERT CHEMICAL STRUCTURE HERE]; R1 is alkyl or aryl, said aryl optionally substituted with one to five substituents independently selected from C1 to C6 alkyl, C1 to C4 haloalkyl, OR4, and/or halogen; and R2, R3, R4, and n are defined herein. Also disclosed are methods of using such compounds as selective agonists for G protein-coupled receptor S1P1, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.

Phenyl-1,2,4-Oxadiazolone Derivatives, Processes For Their Preparation and Methods For Their Use as Pharmaceuticals

The inventive compounds of the present invention are comprised of phenyl and pyridinyl-1,2,4-oxadiazolone derivatives and their physiologically acceptable salts and functional derivatives that are shown to provide peroxisome proliferator activator recepto

Substituted phenyl farnesyltransferase inhibitors

Compounds of formula (I) or pharmaceutically acceptable salts thereof, inhibit farnesyltransferase. Methods for making the compounds, pharmaceutical compositions containing the compounds, and methods of treatment using the compounds are disclosed.